Search

Your search keyword '"Ho, James Chung-Man"' showing total 297 results
Start Over Author "Ho, James Chung-Man"
297 results on '"Ho, James Chung-Man"'

5. Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population

Author

Shi, Jianxin, Shiraishi, Kouya, Choi, Jiyeon, Matsuo, Keitaro, Chen, Tzu-Yu, Dai, Juncheng, Hung, Rayjean J, Chen, Kexin, Shu, Xiao-Ou, Kim, Young Tae, Landi, Maria Teresa, Lin, Dongxin, Zheng, Wei, Yin, Zhihua, Zhou, Baosen, Song, Bao, Wang, Jiucun, Seow, Wei Jie, Song, Lei, Chang, I-Shou, Hu, Wei, Chien, Li-Hsin, Cai, Qiuyin, Hong, Yun-Chul, Kim, Hee Nam, Wu, Yi-Long, Wong, Maria Pik, Richardson, Brian Douglas, Funderburk, Karen M, Li, Shilan, Zhang, Tongwu, Breeze, Charles, Wang, Zhaoming, Blechter, Batel, Bassig, Bryan A, Kim, Jin Hee, Albanes, Demetrius, Wong, Jason YY, Shin, Min-Ho, Chung, Lap Ping, Yang, Yang, An, She-Juan, Zheng, Hong, Yatabe, Yasushi, Zhang, Xu-Chao, Kim, Young-Chul, Caporaso, Neil E, Chang, Jiang, Ho, James Chung Man, Kubo, Michiaki, Daigo, Yataro, Song, Minsun, Momozawa, Yukihide, Kamatani, Yoichiro, Kobayashi, Masashi, Okubo, Kenichi, Honda, Takayuki, Hosgood, Dean H, Kunitoh, Hideo, Patel, Harsh, Watanabe, Shun-ichi, Miyagi, Yohei, Nakayama, Haruhiko, Matsumoto, Shingo, Horinouchi, Hidehito, Tsuboi, Masahiro, Hamamoto, Ryuji, Goto, Koichi, Ohe, Yuichiro, Takahashi, Atsushi, Goto, Akiteru, Minamiya, Yoshihiro, Hara, Megumi, Nishida, Yuichiro, Takeuchi, Kenji, Wakai, Kenji, Matsuda, Koichi, Murakami, Yoshinori, Shimizu, Kimihiro, Suzuki, Hiroyuki, Saito, Motonobu, Ohtaki, Yoichi, Tanaka, Kazumi, Wu, Tangchun, Wei, Fusheng, Dai, Hongji, Machiela, Mitchell J, Su, Jian, Kim, Yeul Hong, Oh, In-Jae, Lee, Victor Ho Fun, Chang, Gee-Chen, Tsai, Ying-Huang, Chen, Kuan-Yu, Huang, Ming-Shyan, Su, Wu-Chou, Chen, Yuh-Min, Seow, Adeline, Park, Jae Yong, and Kweon, Sun-Seog

Subjects
Genetics, Cancer, Clinical Research, Human Genome, Prevention, Lung, Lung Cancer, Tobacco, Tobacco Smoke and Health, 2.1 Biological and endogenous factors, Aetiology, Respiratory, Humans, Genome-Wide Association Study, Genetic Predisposition to Disease, Adenocarcinoma of Lung, Asia, Eastern, Lung Neoplasms, Polymorphism, Single Nucleotide
Abstract

Lung adenocarcinoma is the most common type of lung cancer. Known risk variants explain only a small fraction of lung adenocarcinoma heritability. Here, we conducted a two-stage genome-wide association study of lung adenocarcinoma of East Asian ancestry (21,658 cases and 150,676 controls; 54.5% never-smokers) and identified 12 novel susceptibility variants, bringing the total number to 28 at 25 independent loci. Transcriptome-wide association analyses together with colocalization studies using a Taiwanese lung expression quantitative trait loci dataset (n = 115) identified novel candidate genes, including FADS1 at 11q12 and ELF5 at 11p13. In a multi-ancestry meta-analysis of East Asian and European studies, four loci were identified at 2p11, 4q32, 16q23, and 18q12. At the same time, most of our findings in East Asian populations showed no evidence of association in European populations. In our studies drawn from East Asian populations, a polygenic risk score based on the 25 loci had a stronger association in never-smokers vs. individuals with a history of smoking (Pinteraction = 0.0058). These findings provide new insights into the etiology of lung adenocarcinoma in individuals from East Asian populations, which could be important in developing translational applications.

Published
2023

12. Protective Effects from Prior Pneumococcal Vaccination in Patients with Chronic Airway Diseases during Hospitalization for Influenza—A Territory-Wide Study.

Author

Kwok, Wang-Chun, Lung, David Christopher, Tam, Terence Chi-Chun, Yap, Desmond Yat-Hin, Ma, Ting-Fung, Tsui, Chung-Ki, Zhang, Ru, Lam, David Chi-Leung, Ip, Mary Sau-Man, and Ho, James Chung-Man

Subjects
SEASONAL influenza, CHRONIC obstructive pulmonary disease, PNEUMOCOCCAL pneumonia, PNEUMOCOCCAL vaccines, INFLUENZA vaccines
Abstract

Influenza is an important respiratory viral pathogen in adults, with secondary bacterial pneumonia being a common complication. While pneumococcal vaccines can prevent pneumococcal pneumonia and invasive pneumococcal disease, whether they can also prevent the severe in-hospital outcomes among patients hospitalized for influenza has not been examined. A territory-wide retrospective study was conducted in Hong Kong, which included all adult patients having chronic airway diseases (asthma, bronchiectasis, and chronic obstructive pulmonary disease) hospitalized for influenza and who had received seasonal influenza vaccine. The occurrence of secondary bacterial pneumonia, mortality, and other severe in-hospital outcomes were compared among subjects with or without pneumococcal vaccination. There was a total of 3066 eligible patients who were hospitalized for influenza in public hospitals in Hong Kong from 1 January 2016 to 30 June 2023. Completed pneumococcal vaccination with PSV23/PCV13 conferred protection against secondary bacterial pneumonia, all-cause mortality, and respiratory cause of mortality with adjusted odds ratios of 0.74 (95% CI = 0.57–0.95, p = 0.019), 0.12 (95% CI = 0.03–0.53, p = 0.005), and 0.04 (95% CI = 0.00–0.527, p = 0.0038), respectively. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Chu, Quincy, Cortot, Alexis, Pujol, Jean-Louis, Moro-Sibilot, Denis, Fabre, Elizabeth, Lamour, Corinne, Bischoff, Helge, Kollmeier, Jens, Reck, Martin, Kimmich, Martin, Engel-Riedel, Walburga, Hammerschmidt, Stefan, Schütte, Wolfgang, Syrigos, Konstantinos, Ho, James Chung Man, Au, Kwok-Hung, Novello, Silvia, Ardizzoni, Andrea, Pasello, Giulia, Gregorc, Vanessa, Del Conte, Alessandro, Galetta, Domenico, Takahashi, Toshiaki, Nakagawa, Kazuhiko, Nishio, Makoto, Yoh, Kiyotaka, Seto, Takashi, Imamura, Fumio, Kumagai, Toru, Hotta, Katsuyuki, Goto, Yasushi, Hosomi, Yukio, Sakai, Hiroshi, Takiguchi, Yuichi, Kim, Young Hak, Kurata, Takayasu, Yamaguchi, Hiroyuki, Daga, Haruko, Okamoto, Isamu, Satouchi, Miyako, Ikeda, Satoshi, Kasahara, Kazuo, Atagi, Shinji, Azuma, Koichi, Aoe, Keisuke, Horio, Yoshitsugu, Yamamoto, Nobuyuki, Tanaka, Hiroshi, Watanabe, Satoshi, Nogami, Naoyuki, Ozaki, Tomohiro, Koyama, Ryo, Hirashima, Tomonori, Kaneda, Hiroyasu, Tomii, Keisuke, Fujita, Yuka, Seike, Masahiro, Nishimura, Naoki, Kato, Terufumi, Ichiki, Masao, Saka, Hideo, Hirano, Katsuya, Nakahara, Yasuharu, Sugawara, Shunichi, Park, Keunchil, Kim, Sang-We, Min, Young Joo, Lee, Hyun Woo, Kang, Jin-Hyoung, An, Ho Jung, Lee, Ki Hyeong, Kim, Jin-Soo, Lee, Gyeong-Won, Lee, Sung Yong, Alexandru, Aurelia, Udrea, Anghel Adrian, Juan-Vidal, Óscar, Nadal-Alforja, Ernest, Gil-Bazo, Ignacio, Ponce-Aix, Santiago, Paz-Ares, Luis, Rubio-Viqueira, Belén, Alonso Garcia, Miriam, Felip Font, Enriqueta, Fuentes Pradera, Jose, Coves Sarto, Juan, Lin, Meng-Chih, Su, Wu-Chou, Hsia, Te-Chun, Chang, Gee-Chen, Wei, Yu-Feng, Chiu, Chao-Hua, Shih, Jin-Yuan, Su, Jian, Cicin, Irfan, Goksel, Tuncay, Harputluoglu, Hakan, Ozyilkan, Ozgur, Henning, Ivo, Popat, Sanjay, Hatcher, Olivia, Mileham, Kathryn, Acoba, Jared, Garon, Edward, Jung, Gabriel, Raj, Moses, Martin, William, Dakhil, Shaker, Garon, Edward B, Ponce Aix, Santiago, Nadal, Ernest, Au, Kwok Hung, Enatsu, Sotaro, Zimmermann, Annamaria, Frimodt-Moller, Bente, and Visseren-Grul, Carla

Published
2019
Full Text
View/download PDF

23. Real-world study on effectiveness of molnupiravir and nirmatrelvir-ritonavir in unvaccinated patients with chronic respiratory diseases with confirmed SARS-CoV-2 infection managed in out-patient setting

Author

Kwok, Wang Chun, primary, Tsoi, Man Fung, additional, Leung, Sze Him Isaac, additional, Tsui, Ching Ki, additional, Tam, Terence Chi Chun, additional, Ho, James Chung Man, additional, Lam, David Chi Leung, additional, Ip, Mary Sau Man, additional, and Ho, Pak Leung, additional

Published
2023
Full Text
View/download PDF

30. Variability of Blood Eosinophil Count at Stable-State in Predicting Exacerbation Risk of Chronic Obstructive Pulmonary Disease

Author

Kwok,Wang Chun, Chau,Chi Hung, Tam,Terence Chi Chun, Lam,Fai Man, and Ho,James Chung Man

Subjects
International Journal of Chronic Obstructive Pulmonary Disease
Abstract

Wang Chun Kwok,1 Chi Hung Chau,2 Terence Chi Chun Tam,1 Fai Man Lam,1 James Chung Man Ho1 1Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong Special Administrative Region, People’s Republic of China; 2Tuberculosis and Chest Unit, Grantham Hospital, Hong Kong Special Administrative Region, People’s Republic of ChinaCorrespondence: James Chung Man Ho, Department of Medicine, Queen Mary Hospital, 4/F, Professorial Block, 102 Pokfulam Road, Hong Kong Special Administrative Region, People’s Republic of China, Tel +852 2255 4542, Fax +852 2816-2863, Email jhocm@hku.hkBackground: Chronic obstructive pulmonary disease (COPD) phenotyping using stable-state blood eosinophil level was shown to have prognostic implication in terms of exacerbation risk. However, using a single cut-off of blood eosinophil level to predict clinical outcome has been challenged. There have been suggestions that variability of blood eosinophil count at stable-state could provide additional information on exacerbation risk.Methods: A retrospective cohort study was conducted in a major regional hospital and a tertiary respiratory referral centre in Hong Kong, including 275 Chinese patients with COPD, to investigate the possible role of variability of blood eosinophil count at stable-state to predict COPD exacerbation risk in one year.Results: Higher variability of baseline eosinophil count, which is defined as the difference of the minimal and maximal eosinophil count at stable-state, was associated with increased risk of COPD exacerbation in the follow-up period with adjusted OR (aOR) of 1.001 (95% CI = 1.000– 1.003, p-value = 0.050) for 1 unit (cells/μL) increase in variability of baseline eosinophil count, aOR of 1.72 (95% CI = 1.00– 3.58, p-value = 0.050) for 1 SD increase in variability of baseline eosinophil count and aOR of 1.06 (95% CI = 1.00– 1.13) for 50 cells/μL increase in variability of baseline eosinophil count. The AUC by ROC analysis was 0.862 (95% CI = 0.817– 0.907, p-value < 0.001). The cut-off for variability of baseline eosinophil count identified was 50 cells/μL, with sensitivity of 82.9% and specificity of 79.3%. Similar findings were also shown in the subgroup with stable-state baseline eosinophil count below 300 cells/μL.Conclusion: Variability of baseline eosinophil count at stable-state might predict the exacerbation risk of COPD, exclusively among patients with baseline eosinophil count below 300 cells/μL. The cut-off value for variability was 50 cells/μValidation of the study findings in large scale prospective study would be meaningful.Keywords: COPD, eosinophil, phenotype, COPD exacerbation

Published
2023

45. Association between GWAS-identified lung adenocarcinoma susceptibility loci and EGFR mutations in never-smoking Asian women, and comparison with findings from Western populations

Author

Seow, Wei Jie, Matsuo, Keitaro, Hsiung, Chao Agnes, Shiraishi, Kouya, Song, Minsun, Kim, Hee Nam, Wong, Maria Pik, Hong, Yun-Chul, Hosgood, H. Dean, III, Wang, Zhaoming, Chang, I-Shou, Wang, Jiu-Cun, Chatterjee, Nilanjan, Tucker, Margaret, Wei, Hu, Mitsudomi, Tetsuya, Zheng, Wei, Kim, Jin Hee, Zhou, Baosen, Caporaso, Neil E., Albanes, Demetrius, Shin, Min-Ho, Chung, Lap Ping, An, She-Juan, Wang, Ping, Zheng, Hong, Yatabe, Yasushi, Zhang, Xu-Chao, Kim, Young Tae, Shu, Xiao-Ou, Kim, Young-Chul, Bassig, Bryan A., Chang, Jiang, Ho, James Chung Man, Ji, Bu-Tian, Kubo, Michiaki, Daigo, Yataro, Ito, Hidemi, Momozawa, Yukihide, Ashikawa, Kyota, Kamatani, Yoichiro, Honda, Takayuki, Sakamoto, Hiromi, Kunitoh, Hideo, Tsuta, Koji, Watanabe, Shun-Ichi, Nokihara, Hiroshi, Miyagi, Yohei, Nakayama, Haruhiko, Matsumoto, Shingo, Tsuboi, Masahiro, Goto, Koichi, Yin, Zhihua, Shi, Jianxin, Takahashi, Atsushi, Goto, Akiteru, Minamiya, Yoshihiro, Shimizu, Kimihiro, Tanaka, Kazumi, Wu, Tangchun, Wei, Fusheng, Wong, Jason Y.Y., Matsuda, Fumihiko, Su, Jian, Kim, Yeul Hong, Oh, In-Jae, Song, Fengju, Lee, Victor Ho Fun, Su, Wu-Chou, Chen, Yuh-Min, Chang, Gee-Chen, Chen, Kuan-Yu, Huang, Ming-Shyan, Yang, Pan-Chyr, Lin, Hsien-Chih, Xiang, Yong-Bing, Seow, Adeline, Park, Jae Yong, Kweon, Sun-Seog, Chen, Chien-Jen, Li, Haixin, Gao, Yu-Tang, Wu, Chen, Qian, Biyun, Lu, Daru, Liu, Jianjun, Jeon, Hyo-Sung, Hsiao, Chin-Fu, Sung, Jae Sook, Tsai, Ying-Huang, Jung, Yoo Jin, Guo, Huan, Hu, Zhibin, Wang, Wen-Chang, Chung, Charles C., Lawrence, Charles, Burdett, Laurie, Yeager, Meredith, Jacobs, Kevin B., Hutchinson, Amy, Berndt, Sonja I., He, Xingzhou, Wu, Wei, Wang, Junwen, Li, Yuqing, Choi, Jin Eun, Park, Kyong Hwa, Sung, Sook Whan, Liu, Li, Kang, Chang Hyun, Hu, Lingmin, Chen, Chung-Hsing, Yang, Tsung-Ying, Xu, Jun, Guan, Peng, Tan, Wen, Wang, Chih-Liang, Sihoe, Alan Dart Loon, Chen, Ying, Choi, Yi Young, Hung, Jen-Yu, Kim, Jun Suk, Yoon, Ho-Il, Cai, Qiuyin, Lin, Chien-Chung, Park, In Kyu, Xu, Ping, Dong, Jing, Kim, Christopher, He, Qincheng, Perng, Reury-Perng, Chen, Chih-Yi, Vermeulen, Roel, Wu, Junjie, Lim, Wei-Yen, Chen, Kun-Chieh, Chan, John K.C., Chu, Minjie, Li, Yao-Jen, Li, Jihua, Chen, Hongyan, Yu, Chong-Jen, Jin, Li, Lo, Yen-Li, Chen, Ying-Hsiang, Fraumeni, Joseph F., Jr, Liu, Jie, Yamaji, Taiki, Yang, Yang, Hicks, Belynda, Wyatt, Kathleen, Li, Shengchao A., Dai, Juncheng, Ma, Hongxia, Jin, Guangfu, Song, Bao, Wang, Zhehai, Cheng, Sensen, Li, Xuelian, Ren, Yangwu, Cui, Ping, Iwasaki, Motoki, Shimazu, Taichi, Tsugane, Shoichiro, Zhu, Junjie, Jiang, Gening, Fei, Ke, Wu, Guoping, Chien, Li-Hsin, Chen, Hui-Ling, Su, Yu-Chun, Tsai, Fang-Yu, Chen, Yi-Song, Yu, Jinming, Stevens, Victoria L., Laird-Offringa, Ite A., Marconett, Crystal N., Lin, Dongxin, Chen, Kexin, Wu, Yi-Long, Landi, Maria Teresa, Shen, Hongbing, Rothman, Nathaniel, Kohno, Takashi, Chanock, Stephen J., and Lan, Qing

Published
2017
Full Text
View/download PDF

46. Real-World Study on Effectiveness of Molnupiravir and Nirmatrelvir–Ritonavir in Unvaccinated Patients with Chronic Respiratory Diseases with Confirmed SARS-CoV-2 Infection Managed in Out-Patient Setting.

Author

Kwok, Wang Chun, Tsoi, Man Fung, Leung, Sze Him Isaac, Tsui, Chung Ki, Tam, Terence Chi Chun, Ho, James Chung Man, Lam, David Chi Leung, Ip, Mary Sau Man, and Ho, Pak Leung

Subjects
CHRONICALLY ill, VACCINATION, MOLNUPIRAVIR, VACCINATION status, CHRONIC obstructive pulmonary disease
Abstract

While molnupiravir (MOV) and nirmatrelvir–ritonavir (NMV-r) were developed for treatment of mild to moderate COVID-19 infection, there has been a lack of data on the efficacy among unvaccinated adult patients with chronic respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD) and bronchiectasis. A territory-wide retrospective cohort study was conducted in Hong Kong to investigate the efficacy of MOV and NMV-r against severe outcomes of COVID-19 in unvaccinated adult patients with chronic respiratory diseases. A total of 3267 patients were included. NMV-r was effective in preventing respiratory failure (66.6%; 95% CI, 25.6–85.0%, p = 0.007), severe respiratory failure (77.0%; 95% CI, 6.9–94.3%, p = 0.039) with statistical significance, and COVID-19 related hospitalization (43.9%; 95% CI, −1.7–69.0%, p = 0.057) and in-hospital mortality (62.7%; 95% CI, −0.6–86.2, p = 0.051) with borderline statistical significance. MOV was effective in preventing COVID-19 related severe respiratory failure (48.2%; 95% CI 0.5–73.0, p = 0.048) and in-hospital mortality (58.3%; 95% CI 22.9–77.4, p = 0.005) but not hospitalization (p = 0.16) and respiratory failure (p = 0.10). In summary, both NMV-r and MOV are effective for reducing severe outcomes in unvaccinated COVID-19 patients with chronic respiratory diseases. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

47. Clinical efficacy and safety of pemetrexed with or without either Bevacizumab or Pembrolizumab in patients with metastatic nonsquamous non–small cell carcinoma.

Author

Kwok, Wang Chun, Cheong, Tan Fong, Chiang, Ka Yan, Ho, James Chung Man, Lam, David Chi Leung, Ip, Mary Sau Man, and Tam, Terence Chi Chun

Subjects
PEMETREXED, BEVACIZUMAB, PEMBROLIZUMAB, CARCINOMA, PROGRESSION-free survival
Abstract

Background: Pemetrexed was approved by United States Food and Drug Administration (US FDA) in combination with platinum for the treatment of advanced nonsquamous non–small cell lung carcinoma (NSCLC) and malignant mesothelioma. Bevacizumab and pembrolizumab can be added to chemotherapy for patients with nonsquamous NSCLC with benefits but there has not been any dedicated head‐to‐head comparison between pembrolizumab‐pemetrexed‐platinum (PAC) and bevacizumab‐pemetrexed‐platinum (BAC) on their efficacy and safety. Methods: This was a retrospective single‐center cohort study conducted in Queen Mary Hospital in Hong Kong. The study included 451 patients with advanced stage nonsquamous NSCLC that received first‐line pemetrexed and platinum with or without bevacizumab or pembrolizumab. Patients who received pemetrexed‐platinum (AC) were compared with those who received PAC and BAC. The primary endpoint was the progression‐free survival (PFS). Results: The median PFS for patients that received PAC was significantly longer than those who received BAC and AC (9 months vs. 6.8 months vs. 4.8 months, p < 0.05 among all three groups), with OR of 0.578 (95% CI, 0.343–0.976; p = 0.040) and 0.430 (95% CI, 0.273–0.675; p < 0.001) when compared to BAC and AC, respectively. Patients who received PAC also had a higher disease control rate and higher likelihood to receive continuation maintenance therapy than those on AC. There is no statistically significant difference in the grade 3 to 4 toxicity among the three treatment groups. Conclusions: Although both regimens are superior to pemetrexed‐platinum alone, data from this retrospective single center study suggested a better PFS in advanced stage nonsquamous NSCLC patient treated with first‐line pembrolizumab‐pemetrexed‐platinum than bevacizumab‐pemetrexed‐platinum without an obvious increase in significant toxicity. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

50. Treatment Outcomes in Elderly with Advanced-Stage Non-small Cell Lung Cancer

Author

Tam, Terence Chi-Chun, Ho, James Chung-Man, Wong, Matthew King-Yan, Wong, Wai-Mui, Wang, Julie Kwan-Ling, Lam, Jamie Chung-Mei, Lui, Macy Mei-Sze, Lam, Wah-Kit, Ip, Mary Sau-Man, and Lam, David Chi-Leung

Subjects
Elderly -- Research -- Health aspects, Non-small cell lung cancer -- Research -- Care and treatment -- Patient outcomes -- Development and progression -- Complications and side effects, Health
Abstract

Purpose Lung cancer remains the top cause of cancer morbidity and mortality in the world. Although the identification of epidermal growth factor receptor (EGFR) gene mutations could predict efficacy of tyrosine kinase inhibitor (TKI), testing for predictive biomarkers are not always possible due to tissue availability. The overall therapeutic decision remains a clinical one for a significant proportion of elderly patients with advanced stage lung cancer but no known EGFR mutation status. The purpose of this study was to compare the outcome of drug treatment modalities in progression-free survival (PFS) and overall survival (OS) for elderly with advanced-stage non-small cell lung cancer (NSCLC) and to identify clinical parameters that could predict treatment outcome. Methods Clinical records of patients aged 70 years or older with advanced-stage NSCLC who have received treatment were reviewed. A group of gender- and histology-matched subjects younger than age 70 years were identified as controls. Results Fifty-six elderly patients were included. The median age at diagnosis was 73 years; 60.7 % received only one line of treatment. Baseline performance status (PS) was the only predictor of improved PFS (p = 0.042) and OS (p = 0.002). There was no difference in survival between the upfront chemotherapy and the TKI groups Conclusions In elderly with advanced-stage NSCLC without known EGFR mutation status, use of EGFR-TKI and chemotherapy resulted in comparable survival benefits. Age was not predictive of worse treatment outcome. The baseline PS should be taken into consideration in the therapeutic decision in elderly with NSCLC where the EGFR mutation status is not known., Author(s): Terence Chi-Chun Tam[sup.1] , James Chung-Man Ho[sup.1] , Matthew King-Yan Wong[sup.1] , Wai-Mui Wong[sup.1] , Julie Kwan-Ling Wang[sup.1] , Jamie Chung-Mei Lam[sup.1] , Macy Mei-Sze Lui[sup.1] , Wah-Kit Lam[sup.1] [...]

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results